Brem RF. Management of breast atypical Ductal Hyperplasia: now and the future. Radiology. 2020;294(1):87–8.

Article  PubMed  Google Scholar 

Rageth CJ, O’Flynn EA, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, Tausch C, Dammann F, Baltzer PA, Fallenberg EM. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Research and Treatment 2018:1–18.

Wen X, Cheng W. Nonmalignant breast papillary lesions at core-needle biopsy: a Meta-analysis of underestimation and influencing factors. Ann Surg Oncol. 2013;20(1):94–101.

Article  PubMed  Google Scholar 

Schiaffino S, Calabrese M, Melani EF, Trimboli RM, Cozzi A, Carbonaro LA, Leo GD, Sardanelli F. Upgrade rate of Percutaneously diagnosed pure atypical Ductal Hyperplasia: systematic review and Meta-analysis of 6458 lesions. Radiology. 2020;294(1):76–86.

Article  PubMed  Google Scholar 

Forester ND, Lowes S, Mitchell E, Twiddy M. High risk (B3) breast lesions: what is the incidence of malignancy for individual lesion subtypes? A systematic review and meta-analysis. Eur J Surg Oncol 2018.

Idowu MO, Singh JA, Grimes MM. Overview of Pathology Evaluation of Breast Lesions and Quality Assurance. In: Diagnosis and Management of Breast Tumors: A Practical Handbook and Multidisciplinary Approach edn. Edited by Idowu MO, Shah PA, Hackney MH, Grimes MM, Geyer JCE, Arthur DW, Bear HD. Cham: Springer International Publishing; 2018: 35–72.

DiPasquale A, Silverman S, Farag E, Peiris L. Flat epithelial atypia: are we being too aggressive? Breast Cancer Res Treat. 2020;179(2):511–7.

Article  PubMed  Google Scholar 

Liu C, Dingee CK, Warburton R, Pao J-S, Kuusk U, Bazzarelli A, Sidhu R, McKevitt EC. Pure flat epithelial atypia identified on core needle biopsy does not require excision. Eur J Surg Oncol 2019.

Said SM, Visscher DW, Nassar A, Frank RD, Vierkant RA, Frost MH, Ghosh K, Radisky DC, Hartmann LC, Degnim AC. Flat epithelial atypia and risk of breast cancer: a Mayo cohort study. Cancer. 2015;121(10):1548–55.

Article  PubMed  Google Scholar 

Pawloski KR, Christian N, Knezevic A, Wen HY, Van Zee KJ, Morrow M, Tadros AB. Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia. Breast Cancer Res Treat. 2020;184(3):873–80.

Article  PubMed  PubMed Central  Google Scholar 

Khoury T. Preneoplastic low-risk mammary ductal lesions (atypical Ductal Hyperplasia and Ductal Carcinoma in situ spectrum): current status and future directions. Cancers (Basel) 2022, 14(3).

Australian R, Radiologists, NZCo. Breast Imaging Grading Comparison and Lesion Classification lists. 2018.

Calhoun BC. Core Needle Biopsy of the breast: an evaluation of Contemporary Data. Surg Pathol Clin. 2018;11(1):1–16.

Article  PubMed  Google Scholar 

Morrow M, Schnitt SJ, Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat Reviews Clin Oncol. 2015;12(4):227.

Article  Google Scholar 

Rageth CJ, O’Flynn EA, Comstock C, Kurtz C, Kubik R, Madjar H, Lepori D, Kampmann G, Mundinger A, Baege A et al. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Research and Treatment 2016:1–11.

Dieci MV, Radosevic-Robin N, Fineberg S, Van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D’Alfonso TM, Demaria S, Castaneda C. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on breast Cancer. Seminars in cancer biology: 2018. Elsevier; 2018. pp. 16–25.

Yu X, Zhang Z, Wang Z, Wu P, Qiu F, Huang J. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2016;18(5):497–506.

Article  CAS  PubMed  Google Scholar 

Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JBAG, van Vugt MATM, de Vries EGE, Schröder CP, Fehrmann RSN. Relevance of Tumor-infiltrating Immune Cell composition and functionality for disease outcome in breast Cancer. JNCI: J Natl Cancer Inst. 2017;109(1):djw192–192.

Article  PubMed  Google Scholar 

Hendry S, Pang J-MB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, Mann GB, Gorringe KL, Fox SB. Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. Clin Cancer Res 2017.

Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio G, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2016;28(2):321–8.

Article  Google Scholar 

Rohan TE, Arthur R, Wang Y, Weinmann S, Ginsberg M, Loi S, Salgado R. Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer. Breast Cancer Res. 2021;23(1):1–6.

Article  Google Scholar 

Khoury T, Quinn M, Tian W, Yan L, Zhan H. Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS. Histopathology. 2022;80(2):291–303.

Article  PubMed  Google Scholar 

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van De Vijver K, Estrada M, Gonzalez-Ericsson PI. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group Part 1 assessing the Host Immune Response, TILs in invasive breast carcinoma and Ductal Carcinoma in situ, metastatic Tumor deposits and areas for further research. Adv Anat Pathol. 2017;24(5):235–51.

Article  PubMed  PubMed Central  Google Scholar 

Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, et al. Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. J Pathol. 2019;248(3):326–38.

Article  CAS  PubMed  Google Scholar 

Kader T, Elder K, Zethoven M, Semple T, Hill P, Goode DL, Thio N, Cheasley D, Rowley SM, Byrne DJ, et al. The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. npj Breast Cancer. 2020;6(1):9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rohan TE, Arthur R, Wang Y, Weinmann S, Ginsberg M, Loi S, Salgado R. Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer. Breast Cancer Res. 2021;23(1):15.

Article  PubMed  PubMed Central  Google Scholar 

Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.

Article  PubMed  Google Scholar 

Smith GC, Seaman SR, Wood AM, Royston P, White IR. Correcting for optimistic prediction in small data sets. Am J Epidemiol. 2014;180(3):318–24.

Article  PubMed  PubMed Central  Google Scholar 

Yates JF. External correspondence: decompositions of the mean probability score. Organizational Behav Hum Perform. 1982;30(1):132–56.

Article  Google Scholar 

RCoreTeam: R. A Language and Environment for Statistical Computing. In. Edited by Computing RFfS. Vienna, Austria: R Foundation for Statistical Computing; 2023.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and : Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol 2017, 24(5):235–251.

Degnim AC, Winham SJ, Frank RD, Pankratz VS, Dupont WD, Vierkant RA, Frost MH, Hoskin TL, Vachon CM, Ghosh K. Model for Predicting breast Cancer Risk in Women with atypical Hyperplasia. J Clin Oncol. 2018;36(18):1840–6.

Article  PubMed  PubMed Central  Google Scholar 

Peña A, Shah SS, Fazzio RT, Hoskin TL, Brahmbhatt RD, Hieken TJ, Jakub JW, Boughey JC, Visscher DW, Degnim AC. Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia. Breast Cancer Res Treat 2017, 164(2):295–304.

Khan S, Diaz A, Archer KJ, Lehman RR, Mullins T, Cardenosa G, Bear HD. Papillary lesions of the breast: To excise or observe? The breast journal 2017.

Salagean ED, Slodkowska E, Nofech-Mozes S, Hanna W, Parra‐Herran C, Lu FI. Atypical ductal hyperplasia on core needle biopsy: development of a predictive model stratifying carcinoma upgrade risk on excision. Breast J. 2019;25(1):56–61.

Article  PubMed  Google Scholar 

Poola I, Yue Q, Gillespie JW, Sullivan PS, Aguilar-Jakthong J, Rao J, Shaaban AM, Sauter ER, Ricci AJ. Breast hyperplasias, risk signature, and breast Cancer. Cancer Prev Res. 2019;12(7):471–80.

Article  CAS  Google Scholar 

Lustig DB, Guo M, Liu C, Warburton R, Dingee CK, Pao J-S, Kuusk U, Chen L, McKevitt EC. Development and prospective validation of a risk calculator that predicts a low risk cohort for atypical Ductal Hyperplasia Upstaging to Malignancy: evidence for a Watch and wait strategy of a high-risk lesion. Ann Surg Oncol. 2020;27(12):4622–7.

Article  PubMed  Google Scholar 

Garcia V, Elfer K, Peeters DJE, Ehinger A, Werness B, Ly A, Li X, Hanna MG, Blenman KRM, Salgado R et al. Development of training materials for pathologists to provide machine learning Validation Data of Tumor-infiltrating lymphocytes in breast Cancer. Cancers (Basel) 2022, 14(10).

Sharma N, Cornford E, Cheung S, Price H, Kearins O. The impact of vacuum-assisted excision in the management of indeterminate B3 lesions in the NHS breast screening Programme in England. Clin Radiol. 2021;76(6):470. e423-470 e429.

Article  Google Scholar 

Degnim AC, Hoskin TL, Arshad M, Frost MH, Winham SJ, Brahmbhatt RA, Pena A, Carter JM, Stallings-Mann ML, Murphy LM et al. Alterations in the Immune Cell Composition in Premalignant breast tissue that precede breast Cancer Development. Clin Cancer Res 2017.